

Special Issue

Personalized Medicine for Infertility

Message from the Guest Editor

Infertility, defined as failure to conceive after 12 months or more of regular, unprotected sexual intercourse, affects approximately 15% of couples worldwide and deprives them of their choice to have a child. Infertility is supposed to become the third most common disease in the 21st century after cancer and cardiovascular and cerebrovascular diseases. Generally, infertility may be caused by abnormalities of the ovaries, fallopian tubes, uterus, the endocrine system, and male semen. Considering its multifactorial etiology, precise treatment for infertility takes into account people's individual variations and minimizes adverse effects and medical resources waste. In-depth studies of the pathological factors and molecular mechanisms of infertility provide new ideas and methods for the disorder's prevention, diagnosis, and treatment. This Special Issue aims to highlight recent developments, from basic science to therapeutic strategy, in personalized medicine for infertility. Articles on the investigation of novel etiology, disease biomarkers, and novel opportunities for personalized therapy of infertility are welcome.

Guest Editor

Dr. Ling Wang

Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China

Deadline for manuscript submissions

closed (1 October 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/139996

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).